January 27, 2006 -- Altus Pharmaceuticals staged a very successful IPO this week, pricing in the middle of its original expected range and then adding on another 20% in post-IPO open market trading. Today, one day after the IPO, Altus is priced at $18.35, a rise of $3.35 or 22% from its IPO price of $15. Altus, which was spun out of Vertex Pharma in 1999, uses a proprietary protein crystallization technology to develop new protein drugs. The company has two drugs in clinical trials. We look at their finances and the drugs they have produced so far...
